

CORRECTION

Open Access



# Correction: Polygenic risk for triglyceride levels in the presence of a high impact rare variant

Shengjie Ying<sup>1,2,3</sup>, Tracy Heung<sup>3,4</sup>, Bhooma Thiruvahindrapuram<sup>5</sup>, Worrawat Engchuan<sup>5</sup>, Yue Yin<sup>5</sup>, Christina Blagojevic<sup>3</sup>, Zhaolei Zhang<sup>6,7,8</sup>, Robert A. Hegele<sup>2</sup>, Ryan K. C. Yuen<sup>5,6</sup> and Anne S. Bassett<sup>1,3,4,9,10\*</sup>

**Correction:** *BMC Med Genomics* 16, 281 (2023)  
<https://doi.org/10.1186/s12920-023-01717-2>

## Reference

1. Ying S, Heung T, Thiruvahindrapuram B, et al. Polygenic risk for triglyceride levels in the presence of a high impact rare variant. *BMC Med Genomics*. 2023;16:281. <https://doi.org/10.1186/s12920-023-01717-2>.

Following publication of the original article [1], the authors reported errors in Table 1. The first heading of the table should read “Continuous variables” and not “Categorical variables”. The correct table is given in this correction article. The original article [1] has been corrected.

Published online: 23 November 2023

The original article can be found online at <https://doi.org/10.1186/s12920-023-01717-2>.

\*Correspondence:

Anne S. Bassett  
[anne.bassett@utoronto.ca](mailto:anne.bassett@utoronto.ca)

<sup>1</sup> Institute of Medical Science, University of Toronto, Toronto, ON, Canada

<sup>2</sup> Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

<sup>3</sup> Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada

<sup>4</sup> The Dalglish Family 22Q Clinic, University Health Network, Toronto, ON, Canada

<sup>5</sup> The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada

<sup>6</sup> Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

<sup>7</sup> Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada

<sup>8</sup> Department of Computer Science, University of Toronto, Toronto, ON, Canada

<sup>9</sup> Department of Psychiatry, University of Toronto, Toronto, ON, Canada

<sup>10</sup> Toronto General Hospital Research Institute and Campbell Family Mental Health Research Institute, Toronto, ON, Canada



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 1** Lipid and other phenotypic/clinical variables, and sex effects, in adults with a 22q11.2 microdeletion

<b>Continuous variables</b>									
	<b>Total sample</b>		<b>Males</b>			<b>Females</b>			<b>SD</b>
	<b>n</b>	<b>Mean</b>	<b>SD</b>	<b>n</b>	<b>Mean</b>	<b>SD</b>	<b>n</b>	<b>Mean</b>	
<b>Lipid levels</b>									
TG (mmol/L) <sup>a</sup>	149	1.92	1.18	74	2.25	1.37	75	1.60	0.85
HDLc (mmol/L)	150	1.15	0.35	75	0.99	0.28	75	1.31	0.33
LDLc (mmol/L)	148	2.71	0.87	73	2.67	0.86	75	2.75	0.88
LDLc statin-adjusted (mmol/L) <sup>b</sup>	148	2.81	0.93	73	2.74	0.85	75	2.88	0.99
TC (mmol/L)	151	4.72	0.98	76	4.64	0.98	75	4.80	0.99
TC statin-adjusted (mmol/L) <sup>b</sup>	151	4.84	1.06	76	4.74	1.02	75	4.94	1.09
<b>Other clinical/demographic variables</b>									
BMI (kg/m <sup>2</sup> )	151	30.29	7.39	76	29.82	7.36	75	30.77	7.44
Age <sup>c</sup>	151	35.66	11.2	76	34.92	11.51	75	36.42	10.9
<b>Categorical variables</b>									
	<b>Total sample (n = 151)</b>		<b>Males (n = 76)</b>			<b>Females (n = 75)</b>			<b>%</b>
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>			
Mild-moderate HTG <sup>a,d</sup>	67	45.0	45	60.8	22	29.3			
<b>Other clinical/demographic variables</b>									
On statin medication	16	10.6	7	9.2	9	12.0			
Type 2 diabetes	14	9.3	8	10.5	6	8.0			
Psychotic illness <sup>e</sup>	65	43.0	37	48.7	28	37.3			
European ancestry	135	89.4	71	93.4	64	85.3			

SD Standard deviation, TG Triglyceride, LDLc Low density lipoprotein cholesterol, HDLc High density lipoprotein cholesterol, TC Total cholesterol, BMI Body mass index, HTG Hypertriglyceridemia, T2D type 2 diabetes

<sup>a</sup> Excluded one individual on fibrates (n = 1)

<sup>b</sup> For individuals on statin medications, LDLc and TC levels were divided by 0.7 and 0.8, respectively, as in previous studies [8, 9, 32]

<sup>c</sup> Recorded at the date of TC measurement to the nearest 0.1 years

<sup>d</sup> Mild-moderate HTG is defined as having a TG level between 1.7–10 mmol/L. For this row only, there are n = 74 males and n = 149 total

<sup>e</sup> Defined as schizophrenia or schizoaffective disorder